TIMP1 and metabolic dysfunction-associated steatohepatitis: In humans, tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) has been described as a biomarker of obesity [5–7], dyslipidemia [8–10], NASH [11–13], cardio-vascular disease [14] and type 2 diabetes [15].